Managed Access Programme (MAP)
What Are Managed Access Programmes?
- Structured access pathways for investigational or unlicensed medicines
- Regulatory frameworks designed for serious, life-threatening, or rare conditions
- Ethical oversight ensuring patient safety and appropriate use
- Documentation requirements for regulatory compliance and safety monitoring
- Multi-stakeholder coordination between manufacturers, physicians, and regulators
These programmes bridge the gap between clinical development and commercial availability, providing hope when approved alternatives don't exist.
How it works
Problem:
Solution
How COREX Supports Managed Access Implementation
Programme Strategy & Pathway Selection
Regulatory Consultation & Compliance
Product Sourcing & Importation
GxP-Compliant Storage & Distribution
Documentation Management
Multi-Country Coordination
When to Consider Managed Access Programmes
Patients face serious, life-threatening, or severely debilitating conditions
No approved treatment alternatives are available in the patient's country
The investigational product has demonstrated efficacy in clinical trials
Regulatory approval is pending or delayed in key markets
There's a clinical need to bridge the gap between trial completion and commercial launch